Leuprorelin — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

5 Recruiting

4 Completed trials

9 Sponsors

16 Countries

Phase III

Phase II

Phase I/II

Phase III: 6 Phase II: 3 Phase I/II: 1

Oversight events:

1 temporary halt 2 unexpected events across 2 trials

View oversight register →

Indications tested

Breast cancer 1 Triple positive breast cancer 1 Hormone refractory breast cancer 1 Hormone receptor positive breast cancer 1 Breast cancer metastatic 1

Sponsors using this IMP

Unicancer 2 Alliance Foundation Trials LLC 1 AstraZeneca AB 1 Azienda Provinciale Per I Servizi Sanitari 1 Central Finland Hospital District Central Finland Hospital Nova 1 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 F. Hoffmann-La Roche AG 1 Novartis Pharma AG 1 Reinier de Graaf Groep 1

All trials

10 total

Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending

2023-503676-25-01 Phase II 1 country Azienda Provinciale Per I Servizi Sanitari
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Phase III 5 countries Unicancer
Transdermal estradiol and exercise in mitigating adverse effects of androgen deprivation therapy for prostate cancer radiation therapy (ESTR… Recruiting

2023-504704-28-00 Phase II 1 country Central Finland Hospital District Central Finland Hospital Nova
The RED FLASH study Recruiting

2023-507847-13-00 Phase III 1 country Reinier de Graaf Groep
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting

2023-506698-36-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Phase III 13 countries F. Hoffmann-La Roche AG
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Phase III 5 countries Alliance Foundation Trials LLC
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended

2023-506717-21-00 Phase I/II 6 countries Novartis Pharma AG
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 Phase III 14 countries Astrazeneca AB
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Phase II 1 country Unicancer

Showing 1–10 of 10 trials

← All drugs A–Z